Natasha Manners

Ms. Natasha Manners

Indian Institute of Technology (BHU), Varanasi, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Natasha MannersNatasha Manners
Natasha Manners
VPVishnu Priya
Vishnu Priya
Abhishesh Kumar MehataAbhishesh Kumar Mehata
Abhishesh Kumar Mehata
MRManoj Rawat
Manoj Rawat
Syam MohanSyam Mohan
Syam Mohan
Muthu M.S.Muthu M.S.
Muthu M.S.
Cardiovascular and related diseases (CVRDs) are among the most prevalent chronic diseases in the 21st century, with a high mortality rate. This review summarizes the various nanomedicines for diagnostic and therapeutic applications in CVRDs, including nanomedicine for angina pectoris, myocarditis, myocardial infarction, pericardial disorder, thrombosis, atherosclerosis, hyperlipidemia, hypertension, pulmonary arterial hypertension and stroke. Theranostic nanomedicines can prolong systemic circulation, escape from the host defense system, and deliver theranostic agents to the targeted site for imaging and therapy at a cellular and molecular level. Presently, discrete non-invasive and non-surgical theranostic methodologies are such an advancement modality capable of targeted diagnosis and therapy and have better efficacy with fewer side effects than conventional medicine. Additionally, we have presented the recent updates on nanomedicine in clinical trials, targeted nanomedicine and its translational challenges for CVRDs. Theranostic nanomedicine acts as a bridge towards CVRDs amelioration and its management.